Cardiac Science Announces First Quarter 2000 Results; $625,000 of Powerheart Hospital Bedside Defibrillator-Monitors Sold.

Business Editors & Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--May 9, 2000

Cardiac Science Inc. (OTCBB:DFIB), the developer of Powerheart(R), the only hospital monitor that provides life-saving defibrillation within seconds and without the aid of hospital staff, announced record revenue for the first quarter ended March 31, 2000.

Revenue of $624,642 for the quarter, compared with no revenue for the same period in 1999, is attributed to the sale of 120 Powerheart bedside defibrillator-monitors and related proprietary disposable defibrillation electrodes to its US distribution partner Medtronic Physio-Control, the Arizona Heart Hospital and numerous international distributors.

As of April 1, the company had an existing backlog of orders of approximately $500,000, which it expects to fill within the second quarter.

The company reported a first-quarter net loss of $2,719,530, or 22 cents a share, for the three months ended March 31, 2000. That compares with a net loss of $1,158,161, or 16 cents a share, for the first quarter of 1999.

Marketing expenses relating to the introduction and market launch of the Powerheart totaled approximately $925,000, or 34 percent of the first-quarter loss. Research and Development expenses relating to Powerheart, as well as costs for the company's second product, the Automatic Defibrillation Module, totaled approximately $1,138,000, or 42 percent of the quarter's loss.

The Automatic Defibrillation Module(TM) utilizes the company's proprietary detection and defibrillation software technology, which the company envisions will be integrated into standard bedside patient monitors.

"We continue to pursue aggressively our goal that all in-hospital cardiac patients have access to defibrillation within seconds should they suffer a life-threatening heart rhythm. During this quarter we made demonstrable progress by securing FDA clearance for our initial commercial product, establishing our first U.S. hospital end user site and selling 120 Powerhearts," said Raymond W. Cohen, president and chief executive officer.

"Moreover, we established strategic partnerships in order to integrate wireless alarm notification technology into Powerheart and biphasic defibrillation waveform technology into our Automatic Defibrillation Module. We will continue to make significant investments in marketing programs to drive adoption of the Powerheart, and the development of additional embodiments of our core technology."

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary tachyarrhythmia detection software technology that monitor and automatically treat cardiac arrest patients.

Shipments of our initial commercial product, the Powerheart, began on Dec. 31, 1999. Powerheart continuously monitors in-hospital patients at risk of sudden cardiac arrest, instantly detects the onset of a life-threatening heart rhythm, and when appropriate, automatically delivers defibrillation shocks within seconds and without human intervention to re-establish the heart's normal rhythm.

RHYTHMx ECD(TM) detection and defibrillation software technology, the company's core proprietary technology platform, has multiple applications including use in external defibrillators and existing standard bedside patient monitors widely used in hospitals throughout the world.

The company has an exclusive agreement with Medtronic Physio-Control, a division of Medtronic Inc., the worldwide market leader in external defibrillator products, to distribute the Powerheart in the United States, Canada and nine European countries. Cardiac Science's global network consists of prominent distributors in 41 countries encompassing Asia, the Middle East, Europe, South America and North America.

Cardiac Science is ISO 9001 certified. These are quality standards adopted by more than 90 countries and set forth by the International Organization for Standardization.

Powerheart has U.S. and international regulatory clearance including certification to the European Union's Medical Devices Directive, which allows the company to affix the CE Mark to offer its products for sale in the European Union and European Economic area. For more information, visit www.cardiacscience.com.

                         Cardiac Science Inc.
             Consolidated Condensed Summary of Operations

                                        Three Months Ended March 31,
                                           2000             1999

Sales                                 $    624,642     $     --

Net loss from operations              $ (2,729,953)    $ (1,153,389)

Net loss                              $ (2,719,530)    $ (1,158,161)

Net loss per share                    $      (0.22)    $      (0.16)

Weighted average number
 of shares used in the
 computation of loss per share          12,152,303        7,072,360

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements include, but are not limited to: the Powerheart's safety and efficacy, its ability to increase survival rates for in-hospital cardiac arrest victims, its ability to improve patient-care, lessen patient debilitation and shorten hospital stays; the company's ability to generate revenue, ship product, fulfill its current backlog of orders and develop new products. Cardiac Science cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward- looking statements. Other factors include, but are not limited to: hospital operations; market and clinical users' acceptance of new and existing products; impact of competitive products and pricing; and changing market conditions. Information on these and other factors are detailed in the company's Form 10-K for the year ending Dec. 31, 1999, and other documents filed with the Securities and Exchange Commission. The Powerheart and RHYTHMx ECD and Automatic Defibrillation Module are trademarks of Cardiac Science Inc.